费维皮拉维尔诱导的胸:一个病例报告
Alireza Kashefizadeh1, Laya Ohadi2, Farbod Amiri2
1Shahid Labbafinejad Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
作为COVID-19治疗的一种药物法维皮拉维尔可以导致鼻肌梗塞,即心率减慢. 这种心脏副作用在停止服用药物后消失,强调需要仔细监测.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于其抗病毒性质,法维皮拉维尔正在研究COVID-19治疗.
- 对于favipiravir的心脏安全性,包括潜在的不良影响,存在一些担忧.
更多相关视频
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
相关概念视频
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Acute Respiratory Failure-IV
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
